The present invention relates to polypeptides for the treatment of angiogenesis or lymphangiogenesis-related diseases. In particular, the present invention relates to a a polypeptide which comprises or consists of a sequence of at least 5 consecutive amino acids in SEQ ID NO: 1 and which comprises at least one amino acid selected from the group consisting of Q182, R184, Q195, T199.
